June 2020 Vol 6 No 3
In May 2020, the FDA approved Tabrecta, a new targeted therapy for the treatment of patients with metastatic non–small-cell lung cancer that is associated with the MET biomarker.
Read More ›
Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.
Read More ›
Proton therapy has advantages over traditional radiation in reducing radiation side effects and improving patient outcomes. However, many patients and their oncologists are not familiar with this newer form of radiation therapy.
Read More ›
Julie Behan has been a patient navigator at the American Cancer Society for 24 years. Her story reveals unusual dedication and determination in helping patients with cancer get the care and support they need. Read More ›
In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations. Read More ›
Brandi Benson took a radical approach when she was diagnosed with Ewing sarcoma. Focusing on making positive and holistic changes gave her the emotional and physical strength to battle her cancer.
Read More ›
Dr. Daniel Vorobiof, an oncologist and an expert on sexuality, addresses some of the common misconceptions about sexuality during cancer treatment and offers strategies for dealing with the changes that couples may experience.
Read More ›
When his 91-year-old mother-in-law needed full-time care after her colon cancer diagnosis, Mark Ryan made some adjustments in the family home to ensure her comfort and well-being.
Read More ›
A new long-term study suggests that the choice of treatment for patients with chronic lymphocytic leukemia should be based on the risk level of their disease. Patients at high risk should consider joining a clinical trial with novel agents.
Read More ›
By Dana Taylor
The FDA approved a new Bruton tyrosine kinase (or BTK), Calquence, for first-line treatment of patients with CLL.
Read More ›